MK-1242-035: A Pivotal Phase 3 Randomized, Placebo-controlled Vericiguat Outcomes Study in HFrEF (VICTOR)

About this Study

This study is testing MK-1242 (vericiguat) in people with a certain type of heart failure.  It will compare MK-1242 to placebo (inactive substance) when added to your existing heart failure treatment.  You, your study doctor and the study staff won't know what study drug you are getting.  MK-1242 is experimental.

Sponsor Protocol ID:MK-1242-035
IRB Number:2021V0793
Actively Enrolling
Phase 3
March 02, 2022
Eligibility Criteria
18 years old
Both Male and Female

Inclusion Criteria
  • Must have history of chronic (HF) heart failure on on treatment with no events of heart failure hospitalization within the last 6 months or outpatient IV diuretic use within 3 month before enrolling on study
  • Male or female, at least 18 years of age
  • Must not be pregnant

Exclusion Criteria
  • Systolic blood pressure less than 100 mm Hg or symptomatic low blood pressure
  • Known allergy or sensitivity to vericiguat
  • Awaiting heart transplant
  • Has amyloidosis or sarcoidosis
  • Has primary valvular heart disease
  • Has hypertrophic cardiomyopathy 
  • Received a heart transplant
  • Has tachycardia-induced cardiomyopathy and/or uncontrolled irregular rapid heart rate
  • Has participated in another interventional clinical study or has received another investigational drug less than or equal to 30 days prior to enrolling on study
  • Has recent history of drug or alcohol abuse or dependence within the last year
  • Pregnant or breastfeeding
  • Has malignancy (cancer) or other noncardiac condition limiting life expectancy to less than 3 years